Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 3/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568483 | 0.89 | PRKCZ (0.33) | GPR35NEK1PRKCZSCN9AF10 | |
| SCHEMBL20569212 | 0.88 | NEK1 (0.32) | GPR35NEK1F10 | |
| SCHEMBL23327820 | 0.87 | NEK1 (0.32) | GPR35NEK1 | |
| SCHEMBL20568180 | 0.86 | GPR35 (0.50) | GPR35NEK1SCN9A | |
| SCHEMBL23327691 | 0.85 | GPR35 (0.32) | GPR35 | |
| SCHEMBL23351409 | 0.84 | NEK1 (0.33) | NEK1PRKCZSCN9AEPHB4 | |
| SCHEMBL20568345 | 0.81 | NEK1 (0.39) | GPR35NEK1 | |
| SCHEMBL20568373 | 0.79 | GPR35 (0.35) | GPR35NEK1PRKCZ | |
| SCHEMBL20568839 | 0.79 | — | — | |
| SCHEMBL20568837 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630777-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | claimed |
| WO-2018215800-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | claimed |
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3630777-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215800-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, LCT | GPR35 4727/4885NEK1 3363/4885PRKCZ 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.